血必净联合乌司他丁治疗脓毒症患者获益:一项Meta分析
该Meta分析检索PubMed、Web of Science、CNKI、万方和维普数据库,纳入16项随机对照试验共1192例脓毒症患者。结果显示,与常规治疗组及单用乌司他丁或血必净组相比,血必净联合乌司他丁组在病死率(RR=0.54,95%CI 0.41-0.70,P=.000)、7天APACHE II评分(SMD=-1.21,95%CI -1.62至-0.80,P=.000)、机械通气时间(SMD=-1.21,95%CI -1.62至-0.80,P=.000)、ICU平均停留时间(SMD=-1.21,95%CI -1.62至-0.80,P=.000)、多器官功能障碍综合征发生率(RR=0.54,95%CI 0.41-0.70,P=.000)、白细胞介素-6(SMD=-1.36,95%CI -2.46至-0.27,P=.000)、脂多糖(SMD=-9.92,95%CI -11.7至-7.90,P=.006)和降钙素原(SMD=-0.30,95%CI -0.34至-0.26,P=.012)方面均显著优于对照组。作者认为该结果为脓毒症治疗提供了新的治疗选择。
要点
- 与常规治疗组及单用乌司他丁或血必净组相比,血必净联合乌司他丁组病死率RR=0.54(95%CI 0.41-0.70,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组多器官功能障碍综合征发生率RR=0.54(95%CI 0.41-0.70,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组7天APACHE II评分SMD=-1.21(95%CI -1.62至-0.80,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组机械通气时间SMD=-1.21(95%CI -1.62至-0.80,P=.000),ICU平均停留时间SMD=-1.21(95%CI -1.62至-0.80,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组白细胞介素-6 SMD=-1.36(95%CI -2.46至-0.27,P=.000)、脂多糖SMD=-9.92(95%CI -11.7至-7.90,P=.006)、降钙素原SMD=-0.30(95%CI -0.34至-0.26,P=.012)。
适用人群与场景
- 脓毒症患者(16项随机对照试验共1192例参与者)
研究设计与关键结果
- 研究类型为Meta分析,纳入16项随机对照试验,共1192例参与者。
- 与常规治疗组及单用乌司他丁或血必净组相比,血必净联合乌司他丁组病死率RR=0.54(95%CI 0.41-0.70,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组7天APACHE II评分SMD=-1.21(95%CI -1.62至-0.80,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组机械通气时间SMD=-1.21(95%CI -1.62至-0.80,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组ICU平均停留时间SMD=-1.21(95%CI -1.62至-0.80,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组多器官功能障碍综合征发生率RR=0.54(95%CI 0.41-0.70,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组白细胞介素-6 SMD=-1.36(95%CI -2.46至-0.27,P=.000)。
- 与常规治疗组及单用乌司他丁或血必净组相比,联合组脂多糖SMD=-9.92(95%CI -11.7至-7.90,P=.006),降钙素原SMD=-0.30(95%CI -0.34至-0.26,P=.012)。
证据类型、等级与局限
- 证据类型为Meta分析(基于随机对照试验)。
- 作者结论认为血必净联合乌司他丁优于常规治疗及单用乌司他丁或血必净,为脓毒症治疗提供了新的治疗选择。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血必净联合乌司他丁可为脓毒症治疗提供新的治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The potential benefits and possible risks associated with Xuebijing when combined with ulinastatin for sepsis treatment are not fully understood.
METHODS: Databases, such as PubMed, Web of Science, CNKI, WanFang and VIP, were searched to collect randomized, controlled trials. Studies were screened, data were extracted, and the methodological quality was assessed by two reviewers independently. A meta-analysis was carried out with Stata 11.0 software.
RESULTS: A total of 16 studies involving 1192 participants were enrolled for meta-analysis based on the inclusion and exclusion criteria. The results showed that compared with the group using routine therapies and the group using a single administration of either ulinastatin or Xuebijing, the trial group using Xuebijing combined with ulinastatin was significantly superior in the following aspects: mortality (RR = 0. 54,95% CI (0. 41, 0. 70, P = .000), 7 d APACHE II (SMD = -1.21, 95%CI (-1.62, -0.80), P = .000), duration of mechanical ventilation (SMD = -1.21, 95%CI (-1.62, -0.80), P = .000), average length of time in the intensive care unit (SMD = -1.21, 95%CI (-1.62, -0.80), P = .000), incidence of multiple organ dysfunction syndromes (RR = 0. 54, 95% CI (0.41, 0. 70, P = .000), interleukin-6 (SMD = -1.36,95%CI (-2.46, -0.27), P = .000), lipopolysaccharide (SMD = -9.92, 95%CI (-11.7, -7.90), P = .006), and procalcitonin (SMD = -0.30, 95%CI (-0.34, -0.26), P = .012).
CONCLUSIONS: Our results found that Xuebijing when combined with ulinastatin was superior to both routine therapies and the single administration of either ulinastatin or Xuebijing. This finding provides a new therapeutic option for the treatment of sepsis.
参考来源
- Zheng J, Xiang X, Xiao B, et al. Xuebijing combined with ulinastation benefits patients with sepsis: A meta-analysis. Am J Emerg Med. 2018. PMID: 29373169. doi:10.1016/j.ajem.2017.12.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。